Direct Conversion of R-substituted Ketones
Inorganic Chemistry, Vol. 35, No. 16, 1996 4745
material. Anal. Calcd for C20H16MoN2S2: C, 54.05; H, 3.63; N, 6.30.
Found: C, 54.13; H, 3.64; N, 6.14. 1H NMR (CDCl3): δ 9.21 (s, 1H,
C8H5N2), 8.18-8.08 (m, 2H, C8H5N2), 7.92-7.80 (m, 1H, C8H5 N2),
7.77 (s, 1H, C2H), 7.60-7.48 (m, 1H, C8H5N2), 5.29 (s, 10H, C5H5).
UV-vis [abs] (CH2Cl2): λmax (ꢀ) ) 320 (10 900), 492 nm (5280). IR
(KBr): 3109 (w), 3050 (w), 1540 (s), 1505 (vs), 1481 (s), 1365 (m),
1309 (m), 1205 (m), 1131 (m), 1016 (m), 996 (m), 903 (m), 838 (s),
812 (s), 763 (s) cm-1. Mass spectrum (EI) m/z ) 446 (M+).
3116 (w), 3077 (w), 3026 (w), 3056 (w), 1595 (s), 1574 (m), 1560
(m), 1490 (m), 1479 (m), 1437 (m), 1243 (m), 1065 (m), 1026 (m),
1016 (m), 1002 (m), 913 (m), 903 (m), 865 (m), 835 (s), 825 (s), 810
(s), 758 (s), 737 (vs), 704 (s), 691 (vs), 640 (m), 630 (m), 609 (m),
516 (m), 506 (m) cm-1. Mass spectrum (EI): m/z ) 470 (M+), 228
(M+ - diphenyl-1,2-enedithiolate).
Preparation of Cp2Mo{η2-SC(phenyl)C(H)S} (13). This was
prepared as described for 7 with 2-bromoacetophenone (0.061 g, 0.306
mmol) in place of (bromoacetyl)-2-quinoxaline. Complex 13 was
isolated as a brown solid in 26% yield (0.032 g, 0.081 mmol). Anal.
Calcd for C18H16MoS2: C, 55.10; H, 4.11. Found: C, 54.96; H, 4.48.
1H NMR (CDCl3): δ 7.63 (m, 2H, C6H5), 7.25-7.15 (m, 4H, C6H5
and C2H), 5.25 (s, 10H, 2C5H5). UV-vis [abs] (CH2Cl2): λmax (ꢀ) )
361 (4470), 565 (1310). IR (KBr): 3136 (w), 3067 (w), 3053 (w),
3011 (w), 1589 (s), 1571 (s), 1528 (vs), 1483 (s), 1437 (s), 1420 (s),
1211 (m), 1072 (m), 1017 (m), 1000 (m), 901 (m), 831 (s), 813 (vs),
750 (vs), 692 (s), 654 (m), 604 (m) cm-1. Mass spectrum (EI): m/z )
394 (M+), 228 (M+ - phenyl(H)-enedithiolate).
Preparation of Cp2Mo{η2-S(2-quinoxaline)C(Me)S} (8). This was
prepared as described for 7 using 1-(quinoxalin-2-yl)-2-bromopropanone
(0.122 g, 0.342 mmol) in place of bromoacetyl-2-quinoxaline. Complex
8 was isolated as a red solid in 49% yield (0.077 g, 0.168 mmol) Anal.
Calcd for C21H18MoN2S2: C, 55.03; H, 4.96; N, 6.11. Found: C, 54.89;
H, 4.62; N, 6.36. 1H NMR (CDCl3): δ 9.05 (s, 1H, C8H5N2), 8.05-
7.95 (m, 2H, C8H5N2), 7.65-7.59 (m, 2H, C8H5 N2), 5.29 (s, 10H,
C5H5), 2.35 (s, 3H, CH3). UV-vis [abs] (CH2Cl2) λmax (ꢀ) ) 321-
(14 900), 518 (3770). IR (KBr): 3110 (w), 3050 (w), 2890 (w), 2910
(w), 2960 (w), 1565 (m), 1528 (s), 1435 (m), 1365 (m), 1332 (m),
1267 (m), 1203 (s), 1135 (m), 1015 (m), 999 (m), 955 (m), 936 (m),
Preparation of Cp2Mo{η2-SC(p-chlorophenyl)C(H)S} (14). Pre-
pared as described for 7 with (0.095 g, 0.407 mmol) 2-bromo-4-
chloroacetophenone in place of (bromoacetyl)-2-quinoxaline. Complex
14 was isolated as a brown solid in 27% yield (0.038 g, 0.089 mmol).
Anal. Calcd for C18H15ClMoS2: C, 50.65; H, 3.54. Found: C, 51.01;
H, 4.01. 1H NMR (CDCl3): δ 7.56 (d, [JH-H ) 8 Hz], 2H, C6H4Cl),
7.16 (d, [JH-H ) 8 Hz], 1H, C6H4Cl), 7.15 (s, 1H,C2H), 5.26 (s, 10H,
2C5H5). UV-vis [abs] (CH2Cl2): λmax (ꢀ) ) 3369 (6710), 556 (1520).
IR (KBr): 3112 (w), 3078 (w), 3054 (w), 3044 (w), 1595 (s), 1477
(m), 1439 (m), 1245 (m), 1065 (m), 1027 (m), 1016 (m), 1000 (m),
836 (s), 825 (s), 811 (s), 757 (m), 738 (vs), 702 (s), 691 (s), 610 (m)
cm-1. Mass spectrum (EI): m/z ) 428 (M+), 227 (M+ - chlorophen-
ylenedithiolate).
834 (s), 815 (s), 763 (s), 738 (m), 562 (m), 413 (m) cm-1
. Mass
spectrum (EI): m/z ) 460 (M+), 228 (M+ - quinoxalin-(methyl)-
1,2-enedithiolate).
Preparation of Cp2Mo{η2-SC(2-pyridine)C(H)S} (9). To an
acetonitrile solution of Cp2Mo(SH)2 (0.100 g, 0.342 mmol) was added
(bromoacetyl)-2-pyridine (0.068 g, 0.342 mmol). The mixture was
allowed to stir for 20 min and became a deep red. To the solution
was added ethyldiisopropylamine, dropwise, until the solution become
brown. The brown solution was evaporated to dryness in air. The
solid was chromatographed in air on a 2.5 cm × 20 cm silica gel (60-
200) column and was eluted with 2% methanol-dichloromethane. This
solution was evaporated to dryness to give 9 as a brown solid in 29%
yield (0.039 g, 0.099 mmol). Anal. Calcd for C17H15MoNS2: C, 51.91;
H, 3.84; N, 3.56. Found: C, 51.91; H, 3.90; N 3.38. 1H NMR
(CDCl3): δ 8.48 (m, 1H, C6H4N), 7.68 (m, 1H, C6H4N), 7.65 (m, 1H,
C6H4N), 7.39 (s, 1H, C2H), 6.92 (m, 1H, C6H4N), 5.28 (s, 10H, 2C5H5).
UV-vis [abs] [CH2Cl2]: λmax (ꢀ) ) 380 (5750), 548 (1460). IR
(KBr): 3107 (w), 1614 (m), 1581 (s), 1519 (m), 1491 (m), 1460 (m),
1439 (m), 1424 (m), 1128 (m), 1021 (m), 1001 (m), 921 (m), 837 (s),
818 (m), 759 (m) cm-1. Mass spectrum (EI): m/z ) 395 (M+).
Preparation of Cp2Mo{η2-SC(3-pyridine)C(H)S} (10). This was
prepared as described for 9 with (bromoacetyl)-3-pyridine (0.068 g,
0.342 mmol) in place of (bromoacetyl)-2-pyridine. Complex 9 was
isolated as a brown solid in 27% yield (0.036 g, 0.092 mmol). Anal.
Calcd for C17H15MoNS2: C, 51.91; H, 3.84; N, 3.56. Found: C, 52.44;
H, 4.33; N, 3.54. 1H NMR (CDCl3): δ 8.86 (s, 1H, C6H4N), 8.28 (d,
[JH-H ) 5 Hz], 1H, C6H4N), 7.90 (d, [JH-H ) 8 Hz], 1H, C6H4N), 7.12
(dd, [JH-H ) 5 Hz] [JH-H ) 8 Hz], 1H, C6H4N), 6.85 (s, 1H, C2H),
5.27 (s, 10H, 2C5H5). UV-vis [abs] (CH2Cl2): λmax (ꢀ) ) 371 (5540),
547 (1460). IR (KBr): 3092 (w), 3050 (w), 2970 (w), 1581 (m), 1532
(s), 1475 (s), 1439 (s), 1404 (s), 1233 (m), 1124 (m), 1021 (s), 1005
(s), 907 (m), 828 (vs), 817 (vs), 801 (vs), 765 (vs), 711 (s), 660 (m),
Preparation of Cp2Mo{η2-SC(1-pyrene)C(H)S} (15). Prepared
as described for 7 with 1-(bromoacetyl)pyrene (0.086 g, 0.266 mmol)
in place of (bromoacetyl)-2-quinoxaline. Complex 15 was isolated as
a brown solid in 51% yield (0.070 g, 0.136 mmol). 1H NMR
(CDCl3): 8.45 (d, [JH-H ) 10 Hz], 1H, C16H9), 8.11-7.93 (m, 8H,
C16H9), 6.50 (s, 1H, C2H), 5.34 (s, 10H, 2C5H5). UV-vis [abs]
(CH2Cl2): λmax (ꢀ) ) 345 (19 500), 351 (20 700), 445 (4120). IR
(KBr): 3119 (w), 3104 (w), 3037 (w), 3008 (w), 1596 (m), 1580 (m),
1559 (m), 1542 (m), 1484 (m), 1430 (m), 1420 (m), 1369 (w), 1242
(m), 1180 (m), 1016 (m), 998 (m), 922 (m), 840 (vs), 811 (vs), 761
(s), 718 (vs), 681 (m) cm-1. High resolution mass spectra: calcd for
C28H2098MoS2, m/z ) 518.00604; found, m/z 518.00876.
Structural Determination for Cp2Mo{η2-SC(2-quinoxaline)-
C(H)S}‚0.5CH2Cl2 (7). Crystallographic data are collected in Table
1. Crystals were photographically characterized and determined to
belong to the monoclinic crystal system. Systematic absences indicated
the centrosymmetric space group C2/c or the noncentrosymmetric space
group Cc. Intensity statistics clearly indicated the centric case. An
absorption correction was applied with transmission factors ranging
from 0.8514 to 0.9952, with an average correction of 0.9415. The
structure was determined with the successful location of the molyb-
denum and two sulfur atoms using direct methods. An initial difference
map located all remaining non-hydrogen atoms. All hydrogen atoms
were directly located from two subsequent difference-Fourier maps.
The CH2Cl2 solvent molecule’s central carbon atom was found to lie
at 1/2, y, 1/4 and resulted in the location of two half-occupancy chlorine
atoms about the local 2-fold axis. Solvent hydrogen atoms were placed
in calculated positions that were dependent upon both local geometry
restraints and temperature (293 K in this case) with the methylene
605 (s), 586 (m), 551 (s), 450 (w), 313 (m), 365 (m) cm-1
. Mass
spectrum (EI): m/z ) 395 (M+).
Preparation of Cp2Mo{η2-SC(4-pyridine)C(H)S} (11). This was
prepared as described for 9 with (bromoacetyl)-4-pyridine (0.068 g,
0.342 mmol) in place of (bromoacetyl)-2-pyridine. Complex 11 was
isolated as a brown solid in 23% yield (0.031 g, 0.079 mmol). Anal.
Calcd for C17H15MoNS2: C, 51.91; H, 3.84. Found: C, 52.20; H, 3.46.
1H NMR (CDCl3): δ 8.36(d, [JH-H ) 6 Hz], 2H, C6H4N), 7.50 (d,
[JH-H ) 6 Hz], 2H, C6H4N), 7.14 (s, 1H, C2H), 5.27 (s, 10H, 2C5H5).
UV-vis [abs] (CH2Cl2): λmax (ꢀ) ) 382 (5350), 537 (1520). IR
(KBr): 3119 (w), 3091 (w), 3037 (w), 1597 (s), 1586 (vs), 1541 (vs),
1515 (vs), 1409 (s), 1211 (s), 989 (vs), 919 (s), 833 (s), 813 (s), 804
(s), 772 (vs), 731 (s), 671 (m), 652 (s), 608 (s), 555 (m), 458 (m), 393
(m). Mass spectrum (EI) m/z ) 395 (M+).
hydrogen’s C-H distance ) 0.970 Å and UH set equal to 1.2Uparent
.
These calculated positions were optimized after each cycle of the
refinement but not refined. The hydrogen atoms on the main molecule
were all full occupancy and allowed to refine freely resulting in C-H
distances ranging from 0.783 to 1.015 Å and U(eq) ranging from 0.041
to 0.072. This clearly supporting refinement of these atoms. All
computations used SHELXTL 93 software.43
Preparation of Cp2Mo{η2-SC(phenyl)C(phenyl)S} (12). This was
prepared as described for 7 with densyl bromide (0.068 g, 0.342 mmol)
in place of (bromoacetyl)-2-quinoxaline. Complex 12 was isolated in
40% yield as a brown solid (0.054 g, 0.137 mmol). Anal. Calcd for
C24H20MoS2: C, 61.53; H, 4.30. Found: C, 61.11; H, 4.61. 1H NMR
(CDCl3): δ 7.18-6.95 (m, 10H, 2C6H5) 5.29 (s, 10H, 2C5H5). UV-
vis [abs] (CH2Cl2): λmax (ꢀ) ) 371 (5030), 570 (1940). IR (KBr):
Structural Determination for [Cp2Mo{η2-SC(2-quinoxalineH)-
C(H)S}][BF4] (2). Crystallographic data are collected in Table 1.
(43) (a) Gabe, E. J.; Le Page, Y; Charland, J. P.; Lee, F. L.; White, P. S.
J. Appl. Crystallogr. 1989, 22, 384. (b) Sheldrick, G. M. Acta
Crystallogr. 1990, A46, 467.